Your browser doesn't support javascript.
loading
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
Neven, P; Fasching, P A; Chia, S; Jerusalem, G; De Laurentiis, M; Im, S-A; Petrakova, K; Bianchi, G V; Martín, M; Nusch, A; Sonke, G S; De la Cruz-Merino, L; Beck, J T; Zarate, J P; Wang, Y; Chakravartty, A; Wang, C; Slamon, D J.
Affiliation
  • Neven P; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Herestraat 49, 3000, Leuven, Belgium. patrick.neven@uzleuven.be.
  • Fasching PA; University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
  • Chia S; British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Jerusalem G; CHU Liege and Liège University, Liège, Belgium.
  • De Laurentiis M; Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples, Italy.
  • Im SA; Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Petrakova K; Masaryk Memorial Cancer Institute, Brno, Czech Republic.
  • Bianchi GV; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy.
  • Martín M; Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain.
  • Nusch A; Practice for Hematology and Internal Oncology, Velbert, Germany.
  • Sonke GS; Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, The Netherlands.
  • De la Cruz-Merino L; Hospital Universitario Virgen Macarena, Seville, Spain.
  • Beck JT; Highlands Oncology, Springdale, AR, USA.
  • Zarate JP; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Wang Y; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Chakravartty A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Wang C; Novartis Pharma AG, Basel, Switzerland.
  • Slamon DJ; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Breast Cancer Res ; 25(1): 103, 2023 08 31.
Article in En | MEDLINE | ID: mdl-37653397
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Female / Humans Language: En Journal: Breast Cancer Res Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: Belgium
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms Type of study: Clinical_trials / Guideline / Prognostic_studies Limits: Female / Humans Language: En Journal: Breast Cancer Res Journal subject: NEOPLASIAS Year: 2023 Type: Article Affiliation country: Belgium